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Background. Major depressive disorder (MDD) is a disabling mental illness with high morbidity and mortality rates. Inadequate treatment 
efficacy, unfavourable side-effect profiles and consequent shortfalls in compliance are major stumbling blocks in its treatment. Non-
compliance data in low- to middle-income countries are lacking.
Objective. To investigate the prevalence of antidepressant (AD) non-compliance in the private healthcare sector of South Africa (SA).
Methods. We conducted a prospective cohort study analysing AD medicine claims (N=35 175) for 14 135 patients, obtained from a 
nationally representative pharmaceutical benefit management company, over a 6-year study period (1 January 2006 - 31 December 2011). 
The medicine possession ratio (MPR) was used as a proxy to determine compliance with AD medication. Only patients >18 years of age 
whose treatment had been initiated by a psychiatrist following an appropriate International Classification of Diseases (10th edition) (ICD-
10) diagnosis of a mood disorder were included. A patient was considered compliant if the MPR was between ≥80% and ≤110% over a 
>4-month treatment period.
Results. After the first 4 months, only 34% of patients were compliant. A statistically significant association was found between active 
ingredient consumed and compliance (p<0.0001). Only 26.2% of patients who received amitriptyline-containing products were compliant, 
compared with 38.8% and 38.7% for venlafaxine and duloxetine, respectively.
Conclusion. Compliance data collected from pharmacy claims provide a workable estimate of the broader clinical scenario they represent. 
Although differences between classes of AD were evident, non-compliance was found to be high in the private healthcare environment of 
SA, comparable with global trends.
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Major depressive disorder (MDD) is a disabling 
ill ness affecting people worldwide. The lifetime 
prevalence for major depression in South Africa (SA) 
is 9.8%,[1] as opposed to 16.7%[2] and ~13% for the USA 
and Europe, respectively.[3] MDD not only decreases 
general health but impairs quality of life, performance at work and 
at school, and everyday social interactions. MDD poses a substantial 
risk for suicide,[4] with an estimated 15 - 20% mortality rate.[4] The 
economic impact of affective disorders in Europe (major depression 
and bipolar depression) amounts to EUR106 billion (2004 figures).[5] Of 
this amount, nearly EUR29 billion was spent on direct healthcare costs 
such as hospitalisation, visits to doctors and drug treatment, whereas 
EUR77 billion was attributable to indirect costs including premature 
death, sick leave and workdays lost.[5] The economic cost of depressive 
disorders in the USA in 2007 was estimated to be over USD83 billion,[6] 
with direct and indirect costs on health expenditure of USD26 billion 
and 57 billion, respectively. Projections done in 2011 indicated that 
the total annual cost to South Africans living with severe depression 
and anxiety disorders amounted to USD3.6 billion.[7] These estimates 
suggest either that mental illness has a major economic impact, through 
the effect of disability and stigma on earnings, or that people in lower 
income groups are at increased risk of mental illness.
The management of MDD is severely compromised by non-
compliance.[8] It is recommended that treatment of depression continue 
for at least 4 - 6 months from the time of remission, to prevent relapse.
[9,10] This is extended in high-risk patients, those with recurrent illness 
and/or those with a history of treatment resistance. Several studies 
have shown that remission rates for compliant patients with depression 
are higher than for non-compliant patients,[11,12] and furthermore that 
sustained antidepressant (AD) use over 12 - 36 months may decrease 
the risk of relapse further by up to 70% compared with non-compliant 
patients.[13] In a Spanish study, 56% of patients discontinued their AD 
treatment within the first 4 months, whereas only 22% maintained 
satisfactory adherence over a 5-year period.[14] Many studies concur 
that between 30% and 60% of patients do not comply with AD 
treatment,[15-16] and that up to 30% are likely to stop taking ADs within 
the first month after the start of treatment. In addition, 45 - 60% 
of patients will have stopped their pre scribed treatment by the end 
of the third month.[17-19] Without adequate treatment, patients may 
experience further relapses of depressive episodes.[20] Furthermore, 
preclinical studies demonstrate that premature discontinuation may 
evoke a specific sequence of neurobiological events that underlie 
relapse and treatment resistance.[21,22] Compliance and persistence are 
therefore key concerns in the pharmacological management of MDD.
No studies have investigated AD compliance in low- to middle-
income countries. We therefore studied the prevalence of non-
compliance with AD treatment in the private healthcare sector 
in SA, using the medicine possession ratio (MPR) as a proxy for 
RESEARCH
140       February 2015, Vol. 105, No. 2
patient compliance with ADs, and also looking at possible changes 
in the prescribed daily dosage (PDD) between compliant and 
non-compliant patients, and whether class of AD is an additional 
determinant.
Methods
We conducted a prospective, descriptive cohort study analysing 
nationally representative medicine claims data submitted to a 
privately owned SA pharmaceutical benefit management (PBM) 
company. The database included all prescriptions for an AD (Monthly 
Index of Medical Specialities classification 1.4)[23] for 407 586 patients 
over a 6-year study period, 1 January 2006 - 31 December 2011.
We extracted data for patient demographics (gender and date 
of birth) and pertinent prescription information (such as drug 
trade name, days supplied, dispensing date, quantity of medicine 
prescribed, initial dose, final dose and ICD-10 code per claim). 
The quality of data was ascertained by several automated validation 
processes that were applied by the PBM company. There were no 
missing data fields in the data sets. The variables ‘birth date’ and 
‘dispensing date’ were used to calculate the age of patients on the date 
of treatment and the number of days between refills.
A study population was selected according to the inclusion criteria 
illustrated in Fig. 1. The ICD-10 codes are based on the International 
Statistical Classification of Diseases and Related Health Problems, 
10th edition, published by the World Health Organization.[24] In this 
study the ICD-10 codes F32 (depressive episode) and F33 (recurrent 
depressive disorder) were used to identify patients with MDD as 
diagnosed by a psychiatrist. Thereby it was ensured that data were 
excluded where ADs may have been used for other illnesses, such as 
amitriptyline for the treatment of chronic pain. The study population 
was older than 18 years and consisted of a total of 14 135 patients 
receiving 35 175 AD medicine items dispensed on more than two 
occasions.
The MPR is a well-established method of calculating drug 
compliance in pharmcoepidemiological studies, including chronic 
diseases such as depression,[14] hypertension[25] osteoporosis[26] 
and schizophrenia.[27] However, it is important to note that the 
compliance value obtained from the MPR only gives an indication 
of the possession of medicine by the patient, and that appropriate 
consumption of medicine is assumed to ensue from possession. 
The use of medicine claims data in MPR calculations is helpful in 
that this information is acceptably accurate, convenient, objective, 
non-invasive and relatively inexpensive to obtain when a large study 
population is needed. It is therefore suitable for the calculation of the 
MPR as an indication of patient compliance with medication therapy.
The MPR is defined as the total number of days for which 
medication is supplied (medicine treatment period), divided by the 
number of days in the refill interval, multiplied by 100.[28,29] The MPR is 
considered acceptable if the calculated value is ≥80% but ≤110%.[14] An 
MPR of <80% indicates the presence of refill gaps, so that possession is 
considered unacceptably low (undersupply), whereas an MPR >110% 
is considered unacceptably high (oversupply).
Data management and analysis were performed using SAS Version 
9.1.3 (SAS Institute, USA).  All statistical significance was considered 
with a probability of p<0.05. The practical significance of the results 
was computed when the p-value was statistically significant (p≤0.05).
For the purpose of the study, the MPR and the medicine treatment 
period were used to determine AD compliance of patients. In order 
to treat MDD effectively and prevent relapse, patients must be on 
chronic treatment for at least 120 days.[9,10,28] All patients with an MPR 
of <80% or >110% and/or an AD treatment period of <120 days were 
therefore deemed non-compliant. Conversely, a patient was considered 
compliant with his/her AD treatment if the MPR was between ≥80% 
and ≤110%, and the AD treatment period was >120 days.
Variables (age, age groups, gender, treatment period and active 
ingredients) were expressed using descriptive statistics such as 
frequencies (n), percentages (%), means, standard deviations (SDs) 
and 95% confidence intervals (CIs). Patient age was determined at 
time of first dispensing and divided into three groups: 18 - 40 years, 
41 - 60 years and ≥61 years. Treatment duration was calculated as the 
time (in days) from the first prescription of the ADs until the last. It 
was divided into three groups: ≤30 days, between ≥31 days and ≤120 
days, and >120 days.
The χ2 test was used to determine whether an association existed 
between proportions of two or more groups (age groups v. MPR 
groups). Cramer’s V statistics were used to test the practical significance 
of this association. The two-sample t-test allowed us to compare the 
mean MPR of male and female patients. One-way analysis of variance 
was used to test differences between three or more means and to 
calculate differences in the adjusted PDD changes between compliant 
and non-compliant patients. It was operationalised with the general 
linear model procedure of the SAS Version 9.1.3 system. If a difference 
was indicated, a Tukey multiple comparison test was performed to 
determine which groups most significantly influenced the overall 
difference between groups. Cohen’s d was used to evaluate effect size 
between means (with d≥0.8 defined as practically significant).[30]
The PDD (in mg) of an AD was calculated by multiplying the 
number of tablets (or volume of suspension or syrup) dispensed 
during the treatment period and the strength per tablet (or per mL), 
divided by the number of days supplied. Possible PDD changes from 
the first until the last prescription on the database were determined. 
The correlation coefficient, r, indicated a negative association between 
the initial PDD and change in PDD (r<–0.5; p=0.0001). Possible PDD 
changes were therefore adjusted for variations in initial dosage.
The study was approved by the Ethics Committee of North-West 
University, Potchefstroom Campus, North West Province, SA (NWU-
0046-08-A5), and the boards of directors of the PBM. Data were 
analysed anonymously.
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Fig. 1. The inclusion criteria used in the study.
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Results
MPRs of ADs
The mean (SD) age of the patients was 50.4 
(15.9) years, 71.1% were women, and 71.1% 
received AD medication for >4 months (Table 
1). The mean MPR of the 35 175 ADs was 
98.2% (95% CI 96.6 - 99.9) (Table 2). Only 
49.6% of dispensed ADs were associated 
with an acceptable MPR of between 80% and 
110% (Table 1).
No statistically significant differences were 
found between the MPRs of male and female 
patients: 98.4% (95% CI 95.4 - 101.4) v. 98.2% 
(95% CI 96.2 - 100.1) (Table 2). Patients 
older than 60 years had a lower MPR than 
those aged 18 - 40 years (p=0.0169) (Table 2).
Table 2 clearly indicates that the treat-
ment period had a statistical (p=0.0001) 
and practically significant (d>0.8) influence 
on the MPR of ADs. An abnormally large 
number of patients were noted to be on 
treatment for <30 days (255.4%; 95% 
CI 235.7 - 275.1). This increase in MPR was 
also practically significant compared with 
patients on therapy for between 30 and 120 
days (94.1%; 95% CI 93.3 - 94.9) and those 
on therapy for >120 days (81.1%; 95% CI 
80.7 - 81.5) (d>1.0).
Patient compliance with AD therapy
Only 34% of patients were compliant with 
the AD treatment. In the majority of cases 
(66%), the MPRs were not in the acceptable 
range (80 - 110%) and the treatment period 
was <120 days (Table 3); these patients were 
therefore deemed non-compliant.
No statistically significant association 
was found between gender and patient 
compliance (p=0.1342). Of practical 
significance (p<0.0001; Cramer V=0.0734), 
the results reveal that a larger percentage 
(38.9%) of patients aged >60 years receiving 
ADs, and who were likely to have chronic 
comorbidities such as hypertension or 
diabetes, were compliant compared with 
those in the 18 - 40 years age group (Table 3).
The ten most dispensed AD medications 
represented 86.1% of all those dispensed 
during the study period (Table 1). These 
include venlafaxine, escitalopram, duloxetine, 
mirtazapine, citalopram, fluoxetine, bupro-
pion, sertraline, amitriptyline and trazodone. 
A statistically significant association was 
found between the type of active ingredients 
consumed and compliance (p<0.0001) (Table 
3). Only 26.2% of patients who received 
amitriptyline-containing products were com-
pliant compared with 38.8% and 38.7% in the 
case of the ADs with the highest compliance, 
viz. venlafaxine and duloxetine, respectively 
(Table 3).
Changes in PDDs and compliance
Negative correlations between the initial 
PDD and PDD changes were found for 
all ADs (p=0.0001), with r>–0.5 for 
venlafaxine, escitalopram, mirtazapine 
and amitriptyline. Statistically significant 
Table 1. Patient demographics and medicine use data
Age (years), mean (SD) 50.4 (15.9) 
Age groups (years), n (% of 14 135)
>18 - ≤40 3 449 (24.4)
>40 - ≤60 6 537 (46.2)
>60 4 149 (29.4)
Gender, n (% of 14 135)
Female 10 003 (70.8)
Male 4 132 (29.2)
Treatment period (days), n (% of 14 135)
≤30 830 (5.9)
>30 - ≤120 3 256 (23.0)
>120 10 049 (71.1)
Top ten active ingredients (medicine items), n (% of 35 175)
Venlafaxine 5 222 (14.9)
Escitalopram 5 117 (14.6)
Duloxetine 3 351 (9.5)
Mirtazapine 2 992 (8.5)
Citalopram 2 919 (8.3)
Fluoxetine 2 433 (6.0)
Bupropion 2 153 (6.1)
Sertraline 2 137 (6.1)
Amitriptyline 2 105 (6.0)
Trazodone 1 834 (5.2)
Antidepressant MPR, n (% of 35 175) 
>0 - <80 12 490 (35.5)
≥80 - ≤110 17 435 (49.6)
>110 5 250 (14.9)
Table 2. MPRs of ADs by age group, gender and treatment period
Variable n Mean MPR (%) 95% CI p-value
Overall 35 175 98.2 96.6 - 99.9
Age group (years) 0.0169
>18 - ≤40 7 419 102.4* 98.1 - 106.8
>40 -  ≤60 16 911 98.0 95.7 - 100.4
>60 10 845 95.6* 93.0 - 98.3
Gender 0.9200
Male 9 739 98.4 95.4 - 101.4
Female 25 536 98.2 96.2 - 100.1
Treatment period (days) 0.0001
≤30 2 769 255.4 235.7 - 275.1
>30 - ≤120 9 208 94.1 93.3 - 94.9
>120 23 198 81.1 80.7 - 81.5
*Significant difference in mean MPR (p=0.0169).
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differences (p<0.05; d<0.8) in the adjusted 
PDD changes were found between 
complaint and non-compliant patients on 
venlafaxine, escitalopram, mirtazapine 
and amitriptyline therapy (Table 4). The 
adjusted mean decrease of 6.7 mg (95% CI 
–10.2 - –3.2) in the PDD of venlafaxine in 
the non-compliant patients was significantly 
different compared with the mean increase 
of 1.2 mg (95% CI –3.2 - 5.6) in the compliant 
patients (Table 4). The PDD of mirtazapine 
also decreased, with an adjusted mean of 
0.2 mg (95% CI –1.2 - –0.06) in the non-
compliant patients and 1.2 mg (95% CI 0.3 - 
2.0) in the compliant patients (Table 4). The 
mean adjusted PDD for amitriptyline also 
decreased, with an adjusted mean of 1.3 mg 
(95% CI –2.5 - –0.06) in the non-compliant 
patients and a 1.5 mg (95% CI –0.5 - 3.6) 
increase in the compliant patients (Table 4). 
The mean PDD of escitalopram increased 
more in the compliant patients (1.7 mg; 95% 
CI 1.2 - 2.2) than in those who were non-
compliant (0.1 mg; 95% CI –0.3 - 0.5) from 
the first prescription to the last prescription 
(Table 4).
Discussion
The most important findings of this study 
are that: (i) compliance with chronic AD 
treatment is poor (34%) in the SA private 
healthcare population; and (ii) use of 
medicine claims data may be a feasible and 
reliable way to assess medicine possession 
ratios and subsequent compliance with ADs.
Non-compliance in patients taking ADs is 
a major concern. The 34% compliance rate 
described here is especially poor, although 
Bambauer et al.[31] found that 42% of patients 
stopped their treatment within the first 30 
days, and by day 90, 72% of patients had 
done so. Our study not only emphasises that 
non-compliance is a major obstacle in the 
successful management of MDD, but to our 
knowledge demonstrates for the first time 
that this hindrance to a successful outcome 
is evident in a middle-income country and 
is comparable to data reported for developed 
countries. Interestingly, this observation has 
prompted studies geared to isolating possible 
reasons for the poor compliance,[15,32,33] such 
as feeling better, side-effects, fear of addiction 
and lack of efficacy.[32]
We found the prevalence of MDD in female 
patients to be almost double that in males, in 
keeping with previous studies.[34-36] Stressful 
life events are implicated in the emergence 
and persistence of gender differences 
associated with MDD,[34-36] and it has been 
postulated that women have a biological 
and/or psychological vulnerability towards 
developing an anxiety or mood disorder.[34-36] 
We have noted earlier that non-compliance 
Table 3. Patient compliance with ADs by age group, gender and active ingredient
Variable Compliant Non-compliant p-value
Overall, n (% of 35 175) 11 953 (34.0) 23 222  (66.0)
Age group (years), n (%) 0.0001
>18 - ≤40 202/5 419 (29.7) 5 217/5 419 (70.3)
>40 - ≤60 5 534/16 911 (32.7) 11 377/16 911 (67.3)
>60 4 217/10 845 (38.9) 6 628/10 845 (61.1)
Gender, n (%) 0.1342
Male 3 369/9 739 (34.6) 6 370/9 739 (65.4)
Female 8 584/25 436 (33.8) 16 852/25 436 (66.3)
Top ten active ingredients, n (%) 0.0001
Venlafaxine 2 026/5 222 (38.8) 3 196/5 222 (61.2)
Escitalopram 1 796/5 117 (35.1) 3 321/5 117 (64.9)
Duloxetine 1 295/3 351 (38.7) 2 056/3 351 (61.4)
Mirtazapine 862/2 992 (28.8) 2 130/2 992 (71.2)
Citalopram 1 032/2 929 (35.4) 1 887/2 919 (64.7)
Fluoxetine 763/2 433 (31.4) 1 670/2 433 (68.6)
Bupropion 724/2 153 (33.6) 1 429/2 153 (66.4)
Sertraline 701/2 137 (32.8) 1 436/2 137 (67.2)
Amitriptyline 552/2 105 (26.2) 1 553/2 105 (73.8)
Trazodone 602/1 834 (32.8) 1 232/1 834 (67.2)
Table 4. PDD adjusted for possible change in initial AD dosage in both compliant and non-compliant patients 
Top ten active 
ingredients
Compliant patients Non-compliant patients Compliant patients Non-compliant patients
n
Initial 
PDD
(mg)
Final 
PDD
(mg) n
Initial 
PDD
(mg)
Final 
PDD 
(mg)
Adjusted 
change in 
dosage (mg) 95% Cl
Adjusted 
change in 
dosage (mg) 95% Cl p-value
Venlafaxine 1 986 136.1 137.2 3 179 135.9 129.3 1.2 –3.2 - 5.6 –6.7 –10.2 - –3.2 0.006
Escitalopram 1 796 20.7 21.9 3 321 19.7 20.1 1.7 1.2 - 2.2 0.1 –0.3 - 0.5 0.0001
Duloxetine 1 295 60.7 61.8 2 056 56.3 57.3 3.9 2.0 - 5.9 1.7 0.1 - 3.2 0.08
Mirtazapine 862 26.3 26 2 126 25.1 24.7 1.2 0.3 - 2.0 –0.2 –1.2 - –0.06 0.0007
Citalopram 1 012 26.5 29.1 1 871 28.7 29.1 2.4 1.5 - 3.3 1.5 0.8 - 2.2 0.12
Fluoxetine 731 32.9 33 1 654 33 33.1 0.8 –0.5 - 2.1 0.5 –0.4 - 1.4 0.76
Bupropion 724 235 242.8 1 429 238.6 246.7 27.0 11.2 - 42.8 26.8 16.5 - 37.1 0.98
Sertraline 675 78.7 82.6 1 418 80.5 84.4 5.8 3.6 - 8.1 5.7 4.1 - 7.2 0.90
Amitriptyline 522 43.2 43.3 1 553 40.6 37.9 1.5 –0.5 - 3.6 –1.3 –2.5 - –0.06 0.02
Trazodone 602 274.6 284.2 1 232 390.7 362.5 -13.9 –34.8 - 7.0 4.2 –10.4 - 18.8 0.16
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and inappropriate discontinuation evoke a stress response that may 
adversely affect long-term outcomes.[21,22]
It could also be argued that males would be more likely to 
discontinue their AD medication voluntarily, owing to a stronger 
negative bias associated with the psychological stigma of the illness. 
However, we did not observe any significant association between 
compliance and gender. Two earlier studies have also noted that the 
gender of ambulatory patients treated with AD is a weak predictor of 
non-compliance.[18,37]
Our study also reveals that elderly patients (>60 years) may be 
more compliant than younger populations taking ADs. In fact, elderly 
patients demonstrate reduced dropout ratios and are more likely to 
comply with their medication, and in some cases respond better to 
treatment, than younger patients.[38] Younger patients have a stronger 
negative bias towards issues such as weight gain, sexual dysfunction 
and dissatisfaction with the physician.[39,40]
We also demonstrated that the treatment period has a definite 
influence on the MPR and patient compliance. We found that 
patients were prescribed an oversupply of AD during the first month 
of treatment. This is an interesting observation, especially since 
giving excessive medication may constitute a risk in patients with 
suicidal ideation. However, issues of dosage instability, side-effects 
and changing the regimen or dosage may explain this observation. 
Moreover, hospitalisation and co-prescription of medicines may also 
occur. These findings should be considered when calculating the MPR 
as a measure of patient compliance, taking into account that patients 
on AD treatment first need to be stabilised on the correct AD and 
dose. However, it is of great concern that patients became gradually 
less compliant in the latter part of the 4-month treatment period.
The serotonin re-uptake inhibitors (SSRIs), represented here by 
escitalopram, citalopram, fluoxetine and sertraline, are first-line treat-
ments for MDD because of improved safety and reduced cost,[10] and 
are the most frequently dispensed class of ADs for this disorder.[41] 
Furthermore, in the SA private health sector they have compliance 
rates of between 32.8% and 34% (this study), which is slightly higher 
than the 25.5% reported elsewhere.[42] The low compliance with SSRIs 
in this study population is a noteworthy observation. We found 
compliance ratios for venlafaxine and duloxetine to be significantly 
better (p<0.001) (38.8% and 38.7%) than that for amitriptyline 
(26.2%). Amitriptyline was found to have the worst compliance, 
perhaps because of its greater side-effect burden.[43-45] A negative 
correlation was found between the initial PDD and the change in 
PDD, implying that the higher the initial PDD the smaller the change 
in PDD, particularly for venlafaxine, escitalopram, mirtazapine and 
amitriptyline. A higher initial PDD was also associated with better 
compliance with AD treatment. This finding is supported in the 
literature, as several studies have found that MDD is commonly 
treated with inadequate doses of ADs.[46-48] Furthermore, a study by 
Marcus et al.[49] found that a lower initial dose of AD was associated 
with subsequent switching to another AD or to an entirely new class 
of AD, suggesting that an inadequate dose at the start of treatment 
may contribute to a suboptimal response to initial AD treatment and 
therefore increase the possibility of AD switching and relapse.
Conclusion
We established that compliance with AD treatment remains a major 
obstacle in the treatment of MDD in a middle-income developing 
country like SA. These findings are worrying, as such non-compliance 
may have significant negative effects not only on the long-term 
treatment outcome of MDD but also that of comorbid disorders. 
Some of these aspects are currently under study by our research 
group. We found that only a third of patients suffering from MDD 
are compliant with their AD treatment, with newer-generation ADs 
(particularly serotonin noradrenaline reuptake inhibitors (SNRIs)) 
performing better. We also verified that data from medicine claims 
may be used as a measure of patient compliance in the clinical setting. 
Furthermore, the treatment period has a statistically significant effect 
on the MPR when used as a measure of compliance.
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